Fabtech Techn.

- The company currently has banking limits of ₹22 crore with minimal utilization as of September 2025. - They have obtained sanction from bankers for an enhancement of ₹15 crore, increasing the total working capital limit to around ₹30-35 crore. - The working capital remains largely unutilized, and they have proactively applied for the limit enhancement to be prepared for growth. - No explicit mention of new equity fundraising was indicated. - The company plans to fund growth largely through enhanced and currently underutilized working capital debt facilities. - Investments in subsidiaries like Kelvin are tied to milestones and are internally funded.

- FTCL has pre-empted and ordered 2 roll forming machines and 1 automatic panel assembly line to meet rising demand for modular panels; the panel assembly line will be operational by Q1 FY27, adding capacity worth ₹100-120 crore. - The company is setting up a new manufacturing unit in Hyderabad, expected to be functional by March next year (FY27), to expand capacity. - Strategic investments include increasing stake in entities like Kelvin after milestones are met; plans to fund growth largely through unutilized working capital and sanctioned bank limits. - Focus on value engineering and R&D development to improve costing and margin sustainability. - Ongoing industry-academia collaboration with IIT-Bombay for certificate programs at factories, enhancing technical skills.

- Targeting 30% to 40% year-on-year revenue growth for the next few years, particularly FY26 and FY27. - Expecting to achieve ₹225 to ₹250 crore top-line in FY26. - Order book expected to be between ₹200 to ₹250 crore by March 2026. - Confident about continuing strong growth beyond FY27 without setting a ceiling. - Growth driven by expanding into new sectors beyond pharma (non-pharma sectors such as data centers, solar, electronics, food, and medical disposables). - Market expansion accompanied by increased capacity, including a new manufacturing unit in Hyderabad by March 2026. - Emphasis on reference building and market penetration while moving towards value engineering and product development. - Confident of maintaining a 30-40% growth rate and establishing presence as a sector-agnostic clean room provider.

- The company targets 30-40% year-on-year revenue growth for the next two years (FY26 and FY27), with potential for higher growth beyond FY27 without a defined ceiling. - For FY26, revenue is expected between ₹225 to ₹250 crore, supported by a strong order book and execution pipeline. - PAT margin is projected to be around 7-8% from the second half of the current year onward, improving as reference creation stabilizes and volume increases. - Margin compression in the current year is due to investments in reference building, promotional expenses, and competitive pricing to capture market share. - As references solidify, the company expects to command premium pricing, leading to normalized and potentially higher margins in subsequent years. - The company is focusing on building long-term sustainable earnings through strategic investments and market expansion, especially in non-pharma segments.

- Current order position stands at approximately ₹160 crores. - An additional ₹100-200 crores worth of orders expected to be added in the next six months. - Approximately ₹225 crores of very hot leads are in final stages, though conversion may be less than full amount. - Total pipeline includes about ₹800 crores of hot leads, moving towards very hot status. - Target to enter FY27 with an order book of around ₹250-300 crores. - Execution timelines: Pharma projects typically take 6-9 months; Non-pharma projects, 4-6 months. - Aim to bill at least 50-60% of the order book in the upcoming period.